Dr. Reddy's Launches Debiopharm's Pamorelin® LA in India for the
Treatment of Locally Advanced or Metastatic, Hormone-Dependent
Prostate Cancer
LAUSANNE, Switzerland, December
7, 2012 /PRNewswire/ --
Debiopharm Group™ (Debiopharm), a Swiss-based global
biopharmaceutical group of companies with a focus on the
development of prescription drugs that target unmet medical needs
and companion diagnostics, announces that Dr. Reddy's
Laboratories Ltd. launched Pamorelin® LA in India for the treatment of locally advanced or
metastatic, hormone-dependent prostate cancer on December 3.
Under the terms of the agreement, Dr. Reddy's acquires
exclusive marketing and sales rights for Pamorelin® LA Depot
in India. The product is exported
in bulk from Debio Recherche Pharmaceutique (Debio R.P.) to
Dr. Reddy's. Pamorelin® LA will be made available
primarily to urologists and oncologists across India.
'We recognise the need for prostate cancer treatment in
India and are thrilled to have the
opportunity to bring Pamorelin® LA to Indian patients', said
Rolland-Yves Mauvernay, President and founder of Debiopharm Group™.
'This major step enables us to implement our strategy in one of the
most important markets in Asia.
This is only the logical continuation to a harmonious working
relationship shared with Dr. Reddy's over the years.'
Dr. Reddy's and Debiopharm share the same vision to bring
high-quality and safe ethical products to the highest number of
patients suffering from serious diseases in India.
About Pamorelin® LA (active ingredient: triptorelin)
Triptorelin is an agonist analogue of the natural
gonadotropin-releasing hormone (GnRH). In 1982, Debiopharm signed a
licensing agreement for triptorelin with Tulane University in the US. Debiopharm has then
developed three slow-release formulations (1, 3 and 6 months) of
triptorelin pamoate. The 1- and 3-month-formulations have been
registered in most countries and are currently available under the
names of Trelstar® in North
America, Decapeptyl® /Pamorelin® in Europe and Latin
America and from now on, of Pamorelin® in India. The 6-month-formulation has been
registered and is available in Europe and the US.
About Debiopharm Group™
Debiopharm Group™ (Debiopharm) is a Swiss-based global
biopharmaceutical group of companies with a focus on the
development of prescription drugs that target unmet medical needs.
The group in-licenses, develops and/or co-develops promising
biological and small molecule drug candidates having reached
clinical development phases I, II or III, as well as earlier stage
candidates. It develops its products for global registration and
maximum commercial potential. The products are out-licensed to
pharmaceutical partners for sales and marketing. Debiopharm is also
active in the field of companion diagnostics with a view to
progressing in the area of personalised medicine. Debiopharm
independently funds the worldwide development of all of its
products while providing expertise in pre-clinical and clinical
trials, manufacturing, drug delivery and formulation, and
regulatory affairs.
For more information on Debiopharm Group™, please visit:
http://www.debiopharm.com.
About Debio R.P.
Debio Recherche Pharmaceutique (Debio R.P.), based in
Martigny (Switzerland), is a pharmaceutical research,
development and production company that has been Swissmedic and
ANVISA (Brazil) certified, as well
as inspected and registered by the American Food and Drug
Administration (FDA) and the KFDA (South
Korea). Debio R.P. is active in the discovery, formulation
and development of peptides. Debio R.P. forms part of Debiopharm
Group™ and employs 130 people, half of whom are university
graduates or engineers.
About Dr. Reddy's
Dr. Reddy's Laboratories Ltd. (NYSE: RDY)
(Dr. Reddy's) is an integrated global pharmaceutical company,
committed to providing affordable and innovative medicines for
healthier lives. Through its three businesses - Pharmaceutical
Services and Active Ingredients, Global Generics and Proprietary
Products - Dr. Reddy's offers a portfolio of products and
services including APIs, custom pharmaceutical services, generics,
biosimilars, differentiated formulations and NCEs. Therapeutic
focus is on gastro-intestinal, cardiovascular, diabetology,
oncology, pain management, anti-infective and pediatrics. Major
markets include India,
USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New
Zealand.
For more information, log on to: http://www.drreddys.com
Debiopharm S.A. Contact
Maurice Wagner
Director Corporate Affairs & Communication
Tel.: +41(0)21-321-01-11
Fax: +41(0)21-321-01-69
mwagner@debiopharm.com
Dr. Reddy' s Contact
S. Rajan
rajans@drreddys.com
Tel.: +91-40-49002445
Additional Media Contacts
In London
Maitland
Brian Hudspith
Tel.: +44(0)20-7379-5151
bhudspith@maitland.co.uk
In New York
Russo Partners, LLC
Martina Schwarzkopf, Ph.D.
Account Executive
Tel.: +1-212-845-4292
Fax: +1-212-845-4260
martina.schwarzkopf@russopartnersllc.com
Investors and Financial Analysts:
Kedar Upadhye
kedaru@drreddys.com
Tel.: +91-40-66834297
Saunak Savla
saunaks@drreddys.com
Tel.: +91-40-49002135
Milan Kalawadia (USA)
mkalawadia@drreddys.com
Tel.: +1-908-203-4931
SOURCE The Debiopharm Group